Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065228 · ClinicalTrials.gov registry record
Therapeutic Endpoint in Pediatric IBD Conditions
A clinical trial of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Children's National Research Institute.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06065228: Recruiting study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Children's National Research Institute.
NCT06065228 is a study of Crohn Disease and Inflammatory Bowel Diseases that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 60 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06065228, a study of Crohn Disease and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Children's National Research Institute.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.
Conditions Studied
Interventions
- OTHER AlgometRx Nociometer
Study Locations (1)
District of Columbia
- Children's National Health System - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-12 |
What NCT06065228 shows while recruiting
NCT06065228 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which AlgometRx Nociometer is the first listed.
NCT06065228 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06065228 about?
NCT06065228 is a clinical study titled "Therapeutic Endpoint in Pediatric IBD Conditions". The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory respon...
What is the current status of trial NCT06065228?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2023-11-27. Estimated completion is 2025-12.
What conditions does trial NCT06065228 study?
This clinical trial studies the following conditions: Crohn Disease, Inflammatory Bowel Diseases, Colitis, Ulcerative.
What interventions are being tested in trial NCT06065228?
The interventions under investigation include: AlgometRx Nociometer (OTHER).
Who is sponsoring clinical trial NCT06065228?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06065228 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06065228's enrollment target sits among peer trials
60 43rd of 71 higher than 28 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI